148 related articles for article (PubMed ID: 12824861)
1. Development of acromegaly in patients with prolactinomas.
Andersen M; Hagen C; Frystyk J; Schroeder HD; Hagen C
Eur J Endocrinol; 2003 Jul; 149(1):17-22. PubMed ID: 12824861
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.
Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F
Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206
[TBL] [Abstract][Full Text] [Related]
3. The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases.
Wang M; Mou C; Jiang M; Han L; Fan S; Huan C; Qu X; Han T; Qu Y; Xu G
Eur J Endocrinol; 2012 May; 166(5):797-802. PubMed ID: 22334636
[TBL] [Abstract][Full Text] [Related]
4. The higher incidence of autoimmune thyroid disease in prolactinomas than in somatotrophinomas.
Dogansen SC; Selcukbiricik OS; Bilir BE; Yarman S
Growth Horm IGF Res; 2016 Aug; 29():45-49. PubMed ID: 27105040
[TBL] [Abstract][Full Text] [Related]
5. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists.
Burlacu MC; Maiter D; Duprez T; Delgrange E
Endocrine; 2019 Feb; 63(2):323-331. PubMed ID: 30267354
[TBL] [Abstract][Full Text] [Related]
6. A retrospective hormonal and immunohistochemical evaluation of 47 acromegalic patients: prognostic value of preoperative plasma prolactin.
De Marinis L; Zuppi P; Valle D; Mancini A; Bianchi A; Lauriola L; Pasquini P; Anile C; Maira G; Giustina A
Horm Metab Res; 2002 Mar; 34(3):137-43. PubMed ID: 11972303
[TBL] [Abstract][Full Text] [Related]
7. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
[TBL] [Abstract][Full Text] [Related]
8. Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients.
Ciccarelli E; Grottoli S; Razzore P; Gianotti L; Arvat E; Deghenghi R; Camanni G; Ghigo E
Clin Endocrinol (Oxf); 1996 Jan; 44(1):67-71. PubMed ID: 8706295
[TBL] [Abstract][Full Text] [Related]
9. Distinctive features of prolactin secretion in acromegalic patients with hyperprolactinaemia.
Serri O; Robert F; Comtois R; Jilwan N; Beauregard H; Hardy J; Somma M
Clin Endocrinol (Oxf); 1987 Oct; 27(4):429-36. PubMed ID: 3124991
[TBL] [Abstract][Full Text] [Related]
10. The characteristics of acromegalic patients with hyperprolactinemia and the differences with hyperprolactinemia patients.
Huan C; Cui G; Ren Z
Pak J Pharm Sci; 2015 Mar; 28(2 Suppl):713-8. PubMed ID: 25796163
[TBL] [Abstract][Full Text] [Related]
11. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
Karavitaki N; Thanabalasingham G; Shore HC; Trifanescu R; Ansorge O; Meston N; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2006 Oct; 65(4):524-9. PubMed ID: 16984247
[TBL] [Abstract][Full Text] [Related]
12. Prolactin secretion in the empty sella syndrome, in prolactinomas and in acromegaly.
Brismar K
Acta Med Scand; 1981; 209(5):397-405. PubMed ID: 6787839
[TBL] [Abstract][Full Text] [Related]
13. Cabergoline in the treatment of acromegaly: a study in 64 patients.
Abs R; Verhelst J; Maiter D; Van Acker K; Nobels F; Coolens JL; Mahler C; Beckers A
J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
[TBL] [Abstract][Full Text] [Related]
14. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011.
Tjörnstrand A; Gunnarsson K; Evert M; Holmberg E; Ragnarsson O; Rosén T; Filipsson Nyström H
Eur J Endocrinol; 2014 Oct; 171(4):519-26. PubMed ID: 25084775
[TBL] [Abstract][Full Text] [Related]
15. Serum prolactin and growth hormone response to thyrotropin-releasing hormone in patients with pituitary adenomas.
Chang CC; Chen FW; Hsieh HC
Taiwan Yi Xue Hui Za Zhi; 1989 May; 88(5):443-9. PubMed ID: 2507734
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of glycoprotein hormone alpha subunit in somatoprolactinic and pure somatotroph adenomas.
Vantyghem MC; Cortet C; Bauters C; Gevaert MH; Dewailly D; Lefebvre J; Mazzucca M
J Endocrinol Invest; 1998; 21(7):434-40. PubMed ID: 9766257
[TBL] [Abstract][Full Text] [Related]
17. Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link?
Perić B; Kruljac I; Šundalić S; Pećina HI; Jović A; Štefanović M; Butorac D; Vrkljan M
Endocr Res; 2016 Aug; 41(3):200-6. PubMed ID: 26864960
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
Doknic M; Pekic S; Zarkovic M; Medic-Stojanoska M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2002 Jul; 147(1):77-84. PubMed ID: 12088923
[TBL] [Abstract][Full Text] [Related]
19. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
[TBL] [Abstract][Full Text] [Related]
20. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A
Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
